Literature DB >> 31905294

Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.

Pier Luigi Zinzani1, Robert Chen2, Philippe Armand3, Nathalie A Johnson4, Pauline Brice5, John Radford6, Vincent Ribrag7, Daniel Molin8, Theodoros P Vassilakopoulos9, Akihiro Tomita10, Bastian von Tresckow11, Margaret A Shipp12, Jianxin Lin13, Akash Nahar13, Arun Balakumaran13, Craig H Moskowitz14.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31905294      PMCID: PMC7319053          DOI: 10.1080/10428194.2019.1702178

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  13 in total

1.  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

Authors:  Craig H Moskowitz; Tarun Kewalramani; Stephen D Nimer; Maria Gonzalez; Andrew D Zelenetz; Joachim Yahalom
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

2.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Authors:  C H Moskowitz; S D Nimer; A D Zelenetz; T Trippett; E E Hedrick; D A Filippa; D Louie; M Gonzales; J Walits; N Coady-Lyons; J Qin; R Frank; J R Bertino; A Goy; A Noy; J P O'Brien; D Straus; C S Portlock; J Yahalom
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

6.  Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Authors:  A Josting; C Rudolph; M Reiser; M Mapara; M Sieber; H H Kirchner; B Dörken; D K Hossfeld; V Diehl; A Engert
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

7.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.

Authors:  Patrick B Johnston; David J Inwards; Joseph P Colgan; Betsy R Laplant; Brian F Kabat; Thomas M Habermann; Ivana N Micallef; Luis F Porrata; Stephen M Ansell; Craig B Reeder; Vivek Roy; Thomas E Witzig
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

8.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

9.  Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Authors:  Alison J Moskowitz; Paul A Hamlin; Miguel-Angel Perales; John Gerecitano; Steven M Horwitz; Matthew J Matasar; Ariela Noy; Maria Lia Palomba; Carol S Portlock; David J Straus; Tricia Graustein; Andrew D Zelenetz; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  3 in total

1.  Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.

Authors:  Dinesh Bhurani; Reena Nair; Senthil Rajappa; Suparna Ajit Rao; Nithya Sridharan; Rakesh Reddy Boya; Ganapathi S Raman; Hari Menon; Arun Seshachalam; Ramesh Nimmagadda
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244

Review 2.  Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin's Lymphoma.

Authors:  Shazia Nakhoda; Farsha Rizwan; Aldana Vistarop; Reza Nejati
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

Review 3.  Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation.

Authors:  Eva Domingo-Domènech; Anna Sureda
Journal:  J Clin Med       Date:  2020-05-08       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.